Ticker

Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has earned an average rating of "Hold" from the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The

Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has been assigned an average rating of "Hold" from the six research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The

MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Generation Bio Co. (NASDAQ: GBIO) to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments under certain conditions is fair to Generation Bio shareholders. Halper Sadeh encourages Generation Bio shareholders…

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna -